The Europe Helicobacter Pylori Diagnostics Market would witness market growth of 5.3% CAGR during the forecast period (2023-2030).
The market is expanding as a result of rising demand for non-invasive diagnostics. Patients favor non-invasive diagnostic procedures such as stool antigen and breath testing over invasive procedures like endoscopy. Because of this, new diagnostic technologies have been developed in response to the demand for non-invasive tests, which will continue to fuel the expansion of the market. Due to the availability of enhanced healthcare infrastructure, an increase in unmet healthcare demands, and an increase in infectious disorders, the market is anticipated to grow rapidly.
Additionally, the desire for better healthcare services, large government investments in enhancing the infrastructure for healthcare, and the growth of the medical tourism sector in emerging nations are all contributing to the significant growth of the healthcare sector in developing nations. Additionally, diagnosis of H. pylori infections early and treating them can help avoid more significant side effects like stomach cancer, which can encourage market expansion. There is a rise in requirement for H. pylori testing to aid in early detection and treatment. Also, when people become more aware of these disorders, there will be an increase in the need for H. pylori diagnostic, which will aid the growth of the market.
Gastrointestinal sickness ranking as the third most prevalent cause of mortality, the number one cause of cancer death, and the most frequent reason for hospital admission, the burden of gastrointestinal and liver disease is heavy on patients, the NHS, and the economy. Most gastrointestinal disorders are now more common, which has a substantial impact on future healthcare needs. Hepatitis C infections, acute and chronic pancreatitis, alcoholic liver disease, upper gastrointestinal bleeding, Barrett's esophagus, and colorectal and oesophageal malignancies are among these illnesses. The region's market will increase rapidly due to the increasing prevalence of stomach cancer and other gastrointestinal illnesses, which will surge the demand for diagnosis in Europe.
The Germany market dominated the Europe Helicobacter Pylori Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $53.3 Million by 2030. The UK market is anticipated to grow at a CAGR of 4.5% during (2023 - 2030). Additionally, The France market would showcase a CAGR of 6.1% during (2023 - 2030).
Based on Test Type, the market is segmented into Non-invasive and Invasive. Based on End User, the market is segmented into Diagnostics Laboratories, Hospitals, and Others. Based on Method, the market is segmented into Laboratory Based Test and Point of Care Test. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Helicobacter Pylori Diagnostics Market is Projected to reach USD 805.9 Million by 2030, at a CAGR of 5.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cardinal Health, Inc., Biohit Oyj, Abbott Laboratories, Quidel Corporation, Gulf Coast Scientific, Inc. (Gulf Coast Medical Center), Meridian Bioscience, Inc. (SD Biosensor Co., Ltd.), Avanos Medical, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc. and F. Hoffmann-La Roche Ltd.
By Test Type
By End User
By Method
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
